Skip to content

Study · Non-randomized trial · 2002

2 results

In-vivo ovarian androgen responses to recombinant FSH with and without recombinant LH in polycystic ovarian syndrome.

Cheung AP, Pride SM, Yuen BH, Sy L

Human reproduction (Oxford, England)1 Oct 2002Cited by 6 (Europe PMC)

PMID12351525 (opens in a new tab)DOI10.1093/humrep/17.10.2540 (opens in a new tab)PepBankPUB-12351525
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In women with PCOS, nafarelin significantly suppressed LH, which remained at the assay sensitivity limit of 0.5 IU/l during rFSH stimulation.

    In plain wordsNafarelin suppressed LH in women with PCOS.

    Peptide
    Nafarelin
    Outcome
    DecreaseLH suppression
    Study

    n: not reported in source

    Comparator
    Before nafarelin
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    400 micro g twice daily · 6 weeks before rFSH stimulation startedAs given in this study (human).

    Measurements

    LH
    0.5 IU/l
    remained at the lower limit of assay sensitivity during rFSH stimulation after nafarelin

    Source sentences

    Summary
    Nafarelin significantly suppressed LH levels, which remained at the lower limit of assay sensitivity (0.5 IU/l) during stimulation with rFSH
    1 context sentence
    Summary · context
    Clomiphene-resistant women with PCOS were allocated, in a factorial study design, to receive either daily injections of rFSH (n = 24) or rFSH + rLH (n = 24) in a 1:1 ratio starting: (i) on day 2-3 of progestogen-induced menses (n = 8); (ii) after 6 weeks of GnRH agonist treatment (nafarelin, 400 mic…
  2. 02HumanNon-randomized trialEfficacy outcome

    In women with PCOS, 17-OHP, androstenedione and testosterone levels fell following nafarelin treatment.

    In plain wordsIn women with PCOS, 17-OHP, androstenedione and testosterone levels decreased after nafarelin.

    Peptide
    Nafarelin
    Outcome
    Decrease17-OHP, androstenedione and testosterone suppression
    Study

    n: not reported in source

    Comparator
    Before nafarelin
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    400 micro g twice daily · 6 weeksAs given in this study (human).

    Source sentences

    Summary
    As expected, 17-OHP, DeltaDelta(4) and testosterone levels fell following nafarelin treatment.
    1 context sentence
    Summary · context
    Clomiphene-resistant women with PCOS were allocated, in a factorial study design, to receive either daily injections of rFSH (n = 24) or rFSH + rLH (n = 24) in a 1:1 ratio starting: (i) on day 2-3 of progestogen-induced menses (n = 8); (ii) after 6 weeks of GnRH agonist treatment (nafarelin, 400 mic…

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.